A

Avicenna Clinical Research | Southwest Gastroenterology

Research site

(Unclaimed)

Location

9921 Southwest Highway, Oak Lawn, Illinois, United States of America

Site insights

Top conditions

Top treatments

Risankizumab

Etrolizumab

Relamorelin

Metoclopramide

CP-690,550

RPC4046

Ustekinumab

695501

CIN-103

Vedolizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 31 total trials

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

This is a 26-week, multi-center, randomized, double-blind, placebo-controlled study with a 4-week treatment-free Safety Follow-up period to assess th...

Enrolling

Chronic Idiopathic Constipation (CIC)

Drug: Tenapanor 50 mg BID

Drug: Tenapanor 5 mg BID

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease (FORTIFY)

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting

Crohn's Disease

Drug: Placebo for Risankizumab IV

Drug: Risankizumab SC

Prospective, Open-label, Non-significant Risk, Multicenter Study Comparing the Polyp Detection of the Study Device to That of the Colonoscopy Reference

Note: This is the same study protocol as NCT04607746 with slight changes to how the videos will be read and a 2nd generation capsule is being studied...

Enrolling

Colonic Polyps

Device: Capsule swallow

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) (SEQUENCE)

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankiz...

Active, not recruiting

Crohn's Disease (CD)

Drug: Risankizumab

Drug: Ustekinumab